Sunshine Biopharma wins Canadian approval for generic Dienogest tablets

SBFM•2026-08-04

Expected shipment timing and market context

The company expects product shipments to Canadian pharmacies by end-2026 through its Nora Pharma distribution network.

Dataintelo estimates the global dienogest market at USD 2.8 billion in 2025, rising to USD 5.2 billion by 2034.

Canadian approval for generic dienogest tablets

Sunshine Biopharma secured Canadian regulatory clearance for generic dienogest 2 mg tablets, a Visanne equivalent for endometriosis-related pelvic pain.

Sources

Sunshine Biopharma wins Canadian approval for generic Dienogest tablets

Docs

Sunshine Biopharma wins Canadian approval for generic Dienogest tablets

Expected shipment timing and market context

Canadian approval for generic dienogest tablets

Related News

Nasdaq Trade Halt Continues PLTS.O Reason Not Available at 09:41 AM

US Stocks Snapshot-S&P 500 hits record high on strong AI-linked earnings, Mideast deal hopes

BancFirst director David E. Rainbolt reports sale of 11,497 common shares worth $1.32 million

Sources

Sunshine Biopharma wins Canadian approval for generic Dienogest tablets

Access Newswire schedules second-quarter earnings call and webcast

Kimberly-Clark cuts annual forecasts as China quality claims hurt diaper sales